Immunocore Holdings plc

NASDAQ:IMCR

Biotechnology

Healthcare
$27.51 +0.63%

+$0.18 today

Market cap
$1.42B
Beta
0.75
P/E (TTM)
-77.5
EPS (TTM)
-$0.37
52W Low $27.56High $40.72

Volume 0.30M

Average 0.40M

IMCR Debt Repayment

Cash used to repay borrowings during the period.

Immunocore Holdings plcNASDAQ: IMCR

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment outflow grows to $0

Q1 FY2026 debt repayment was $0, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $0.

Context

  • Debt repayment amounted to 0.0% of revenue in FY2025, down 142.1 pp from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$0+100.0% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

Mixed currencies · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Debt Repayment vs competitors

How IMCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +100.0% is the 3rd highest of 7, against a peer median of +7.6%.
  • Debt repayment amounts to 0.0% of revenue for IMCR, versus a peer median of 1.3%.
IMCR Competitors
Debt Repayment for IMCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€68.06M EUR+862.0%-43.2%2.6%
IPHAInnate Pharma S.A.FY2025€8.56M EUR-4.2%+61.7%307.1%
IBRXImmunityBio, Inc.LTM Sep 2026$5.95M USD+12297.9%-78.5%3.3%
IMTXImmatics N.V.LTM Mar 2026€1.47M EUR-55.0%—4.0%
IMMPImmutep LimitedFY2025A$270.67K AUD+19.5%+6.7%5.4%
IMCRImmunocore Holdings plcLTM Mar 2026$0 USD+100.0%—0.0%
XNCRXencor, Inc.LTM Jun 2026$0 USD——0.0%
RCUSArcus Biosciences, Inc.LTM Jun 2026$0 USD-100.0%—0.0%
JANXJanux Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
CGENCompugen Ltd.LTM Dec 2025$0 USD——0.0%
MGNXMacroGenics, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding IMCR) —+7.6%-18.2%1.3%

Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Net Income(180.03M)(52.54M)(34.32M)(51.09M)(26.42M)
Depreciation & Amortization7.59M5.34M3.24M4.2M2.43M
Deferred Income Tax(12.69M)(3.53M)0011M
Stock-Based Compensation48.89M32.89M25.69M34.19M0
Change in Working Capital(21.96M)(24.17M)4.58M45.13M(6.92M)
Accounts Receivables(4.86M)(26.26M)(14.14M)(12.35M)(5.46M)
Inventory00000
Accounts Payables1.47M4.91M2.08M7.27M(1.83M)
Other Working Capital(18.57M)(2.81M)16.64M50.21M366K
Other Non-Cash Items15.09M(7.19M)3.14M(6.38M)11.94M
Operating Cash Flow(143.11M)(49.21M)2.33M26.06M(7.97M)
Capital Expenditures(1.39M)(2.2M)(4.29M)(5.17M)(3.23M)
Acquisitions (Net)00000
Purchases of Investments000(350M)(22.32M)
Sales of Investments000013.39M
Other Investing Activities106K6K(925.46K)44K0
Investing Cash Flow(1.28M)(2.2M)(4.29M)(355.13M)(12.16M)
Debt Repayment000352.5M0
Common Stock Issued286.89M139.52M06.8M9.2M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.3M5.93M27.18M(15.42M)0
Financing Cash Flow288.19M145.44M27.18M343.88M9.2M
Effect of Forex Changes625K(12.65M)6.56M(1.71M)19.81M
Net Change in Cash144.42M81.39M31.78M13.11M8.89M
Free Cash Flow(144.49M)(51.41M)(1.97M)20.89M(11.2M)

Immunocore Holdings plc

NASDAQ:IMCR

Intrinsic Alpha fair value

Locked

Current Price

$27.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.